Lung Cancer Liquid Biopsy Market Report 2026

The lung cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $1.12 billion in 2025 to $1.31 billion in 2026 at a compound annual growth rate (CAGR) of 17%. The growth in the historic period can be attributed to increasing lung cancer incidence rates, limitations of tissue biopsy procedures, advancements in molecular diagnostics, availability of circulating biomarker technologies, growth of oncology research activities.

The lung cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $2.42 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to increasing demand for precision oncology solutions, expansion of liquid biopsy clinical applications, rising adoption of companion diagnostics, growing integration of ai-driven data analysis, increased focus on early cancer screening programs. Major trends in the forecast period include increasing adoption of non-invasive diagnostic techniques, rising use of ngs-based liquid biopsy tests, growing demand for early cancer detection, expansion of personalized oncology diagnostics, enhanced integration of bioinformatics platforms.

The rising incidence of lung cancer is expected to drive the growth of the lung cancer liquid biopsy market in the coming years. Lung cancer is a disease characterized by the uncontrolled proliferation of abnormal cells in the lungs, often linked to smoking and environmental exposures. The increase in lung cancer cases is primarily due to ongoing tobacco use, as smoking exposes lung tissue to carcinogens that trigger abnormal cell growth. Lung cancer liquid biopsy aids in detecting cancer-related genetic mutations and circulating tumor DNA from a blood sample, enabling early diagnosis, treatment selection, and monitoring of disease progression or therapeutic response. For instance, in January 2023, according to the American Cancer Society (ACS), a U.S.-based nonprofit organization, it was estimated that 238,340 individuals - 117,550 men and 120,790 women - would be diagnosed with lung cancer in 2023, with 127,070 deaths projected from the disease. Therefore, the rising incidence of lung cancer is driving the growth of the lung cancer liquid biopsy market.

Key companies in the lung cancer liquid biopsy market are focusing on technological innovations, such as blood-based lung cancer screening tests, to enhance early detection, improve diagnostic accuracy, and provide non-invasive, real-time monitoring of tumor progression and treatment response. A blood-based lung cancer screening test is a non-invasive method that analyzes biomarkers in the blood to detect lung cancer at an early stage. For example, in October 2023, DELFI Diagnostics Inc., a US-based biotechnology company, launched FirstLook Lung, a blood-based liquid biopsy test designed to facilitate early lung cancer detection. This test uses fragmentomics to detect early-stage lung cancer with high sensitivity and a 99.8% negative predictive value, offering a convenient and accessible first screening step for at-risk individuals. It aims to improve early diagnosis, increase screening rates, and direct further imaging resources to those most likely to benefit.

In February 2024, Veracyte Inc., a US-based molecular diagnostics company, acquired C2i Genomics Inc. for an undisclosed amount. Through this acquisition, Veracyte seeks to enhance its cancer diagnostics portfolio by adding advanced whole-genome MRD liquid biopsy capabilities for improved detection and monitoring across multiple cancer types. C2i Genomics Inc. is a US-based firm specializing in cancer detection and monitoring, including lung cancer biopsy testing.

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation.

North America was the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lung cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the lung cancer liquid biopsy market by increasing costs of imported sequencing instruments, reagents, bioinformatics software, and diagnostic consumables. North America and Europe are most affected due to dependence on advanced molecular diagnostics imports, while Asia-Pacific experiences cost pressure on test kit procurement and equipment upgrades. These tariffs are increasing diagnostic costs and slowing laboratory expansion. At the same time, they are promoting localized reagent manufacturing, domestic sequencing platform development, and regional diagnostic innovation.

The lung cancer liquid biopsy market research report is one of a series of new reports that provides lung cancer liquid biopsy market statistics, including lung cancer liquid biopsy industry global market size, regional shares, competitors with a lung cancer liquid biopsy market share, detailed lung cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer liquid biopsy industry. This lung cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lung cancer liquid biopsy is a non-invasive technique that analyzes blood or other body fluids to detect tumor-derived genetic material or cells. This method enables early diagnosis, genetic profiling, and monitoring of lung cancer by capturing cancer-specific biomarkers, offering an alternative to surgical tissue biopsies.

The primary lung cancer liquid biopsy products include instruments, consumables, kits and reagents, and software and services. Instruments refer to the hardware and analytical devices used to process and analyze liquid biopsy samples. The technology employs multi-gene parallel analysis methods such as next-generation sequencing (NGS), as well as single-gene analysis techniques like PCR and microarrays. Biomarkers include cell-free DNA, circulating tumor DNA, extracellular vesicles, circulating tumor cells, and other related markers. These products are applied in areas such as therapy selection, treatment monitoring, early cancer screening, recurrence monitoring, and other applications. End users include diagnostic and imaging centers, hospitals, academic and research institutions, and other user groups.

The lung cancer liquid biopsy market consists of revenues earned by entities by providing services such as mutation detection and genomic profiling, treatment monitoring, and early diagnosis and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer liquid biopsy market also includes sales of NGS-based assays, CTC detection devices and others. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.